Hutchison Pharmaceuticals Announces Approval Of Cd73 Monoclonal Antibody Mupadolimab In Phase I/Ib Clinical Trial In China
The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.